Zheng Bin Yao
Directeur Général chez ARRIVENT BIOPHARMA, INC.
Fortune : 12 M $ au 30/06/2024
Profil
Zheng Bin Yao is the founder of Arrivent BioPharma, Inc. (founded in 2021) and holds the title of Chairman & Chief Executive Officer.
He is currently working as an Independent Director at NexImmune, Inc. (since 2017), Director at Immune-Onc Therapeutics, Inc. (since 2019), Independent Non-Executive Director at VISEN Pharmaceuticals (since 2021), and Independent Director at Alumis, Inc. (since 2021).
Previously, he served as Chairman, President & Chief Executive Officer at Viela Bio, Inc. (2018-2021) and SVP & Head-Respiratory & Inflammation at MedImmune LLC (2010-2018).
He also held the position of Vice President-Research at Tanox, Inc. (2000-2007).
Dr. Yao obtained a doctorate degree from the University of Iowa and a graduate degree from Anhui Medical University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ARRIVENT BIOPHARMA, INC.
1,83% | 26/01/2024 | 613 138 ( 1,83% ) | 11 M $ | 30/06/2024 |
Alumis, Inc.
 Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA. 0,05% | 01/07/2024 | 23 529 ( 0,05% ) | 312 936 $ | 30/06/2024 |
NEXIMMUNE, INC.
0,04% | 01/03/2024 | 505 ( 0,04% ) | 1 394 $ | 30/06/2024 |
Postes actifs de Zheng Bin Yao
| Sociétés | Poste | Début |
|---|---|---|
| NEXIMMUNE, INC. | Directeur/Membre du Conseil | 01/01/2017 |
| ARRIVENT BIOPHARMA, INC. | Directeur Général | 01/06/2021 |
Immune-Onc Therapeutics, Inc.
 Immune-Onc Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Immune-Onc Therapeutics, Inc. operates as a biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment. The company was founded by Charlene Liao and Gui-Liang Yu in 2016 and is headquartered in Palo Alto, CA. | Directeur/Membre du Conseil | 01/04/2019 |
Alumis, Inc.
Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA. | Directeur/Membre du Conseil | 01/06/2021 |
VISEN Pharmaceuticals
 VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Directeur/Membre du Conseil | 01/04/2021 |
Anciens postes connus de Zheng Bin Yao
| Sociétés | Poste | Fin |
|---|---|---|
| VIELA BIO, INC. | Directeur Général | 15/03/2021 |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
Tanox, Inc.
 Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Directeur Technique/Scientifique/R&D | 19/10/2007 |
| ASTRAZENECA PLC | Corporate Officer/Principal | - |
Formation de Zheng Bin Yao
| University of Iowa | Doctorate Degree |
| Anhui Medical University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| NEXIMMUNE, INC. | Health Technology |
 | Health Technology |
| ARRIVENT BIOPHARMA, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Health Technology |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Health Technology |
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Immune-Onc Therapeutics, Inc. operates as a biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment. The company was founded by Charlene Liao and Gui-Liang Yu in 2016 and is headquartered in Palo Alto, CA. | Health Technology |
Viela Bio, Inc.
 Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
VISEN Pharmaceuticals
VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Health Technology |
